论文部分内容阅读
目的观察单唾液酸四己糖神经节苷脂(GM1)治疗新生儿缺氧缺血性脑病(HIE)的疗效及安全性。方法将54例中重度HIE患儿随机分为治疗组28例与对照组26例,2组均给予基本治疗,治疗组在此基础上加用GM120mg静脉滴注,1次/d,疗程10～14d。结果治疗组与对照组相比,临床神经症状恢复时间明显缩短(P<0.05),3、7、14dNBNA评分均明显增高(P<0.05)。加用GM1者未见明显不良反应。结论GM1能促进HIE急性期临床神经症状恢复,缩短病程,是治疗HIE有效安全的药物。
Objective To observe the efficacy and safety of monosialotetrahexosyl ganglioside (GM1) in the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). Methods 54 cases of moderate and severe HIE were randomly divided into treatment group 28 cases and control group 26 cases, two groups were given basic treatment, the treatment group on this basis plus GM120mg intravenous infusion, 1 / d, treatment of 10 ~ 14d. Results Compared with the control group, the recovery time of clinical neurological symptoms was significantly shortened (P <0.05), and the scores of NBNA were significantly increased at 3, 7 and 14 days (P <0.05). Add GM1 no significant adverse reactions. Conclusion GM1 can promote the recovery of clinical neurological symptoms in HIE in the acute phase and shorten the course of the disease. It is an effective and safe drug for HIE.